MR-Guided Focused Ultrasound (MRgFUS) is a treatment for Essential Tremor currently available on Medicare in the USA, the NHS in Japan, and in other countries around Europe.
Currently, the most common non-pharmacological treatment for Essential Tremor in the UK is Deep Brain Stimulation (DBS), an invasive procedure which, although very effective, involves the surgical opening of the skull, permanently implanted hardware requiring surgical battery replacements for the remaining lifetime of the patient, as well as a long recovery period and hospital stay.
MRgFUS is a safe, cost-effective and non-invasive treatment which delivers the same patient outcomes as DBS, often in an outpatient setting, enabling patients to quickly return to work and activities of daily life.
In June 2018, the treatment received positive guidance from the National Institute for Health and Care Excellence (NICE). This is an evidence-based recommendation which sets out the care and services suitable for people with a specific condition.
This public consultation period is the opportunity to ensure that the NICE guidance is implemented as a final commissioning policy within the NHS, in as timely a fashion as possible.